Posted by AGORACOM-JC
at 4:10 PM on Friday, July 16th, 2021
FOBI AI is a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement for enterprise level retailers.
More than just lip service, these are just a sample of the major milestones reached by $FOBI over the past 9 months:
Strategic Alliance with global data leader – NeilsonIQ – to “Transform Retail Sector”
A partnership with NTT DATA, a top-ranked global IoT services company, and subsidiary of Nippon Telegraph and Telephone, the world’s 4th largest telecom company, ranked 55th In Fortune Global 500.
Approved for Oracle Partner Network
Pilot Projects with Sobeys, TELUS, Certas and other national level retailers
Multi-Year Direct Seller Agreement With TELUS, in which TELUS resells FOBI solutions to national business customers
Posted by AGORACOM-JC
at 5:47 PM on Tuesday, July 13th, 2021
PyroGenesis is the world leader in the development of advanced plasma processes and products. In short, their plasma torch technology has been the foundation of multiple successful applications around the world that significantly reduce both greenhouse gases and costs of doing business for some of the world’s biggest companies in these following verticals:
Ultra High-Tech 3D Printing (Additive Manufacturing)
Iron Ore Pelletization
Aluminum Smelters Recovery Of Dross
High-Purity Silicon For EV Batteries
….. More
Today, PyroGenesis CEO Peter Pascali provides investors with a comprehensive update of each vertical and some of the major business developments taking place within each of them. Watch our great interview with CEO Peter Pascali
Posted by AGORACOM-JC
at 4:06 PM on Monday, July 12th, 2021
As the name implies “PropTech” is a combination of two words and stands for “property technology.” As simple as that is, the implementation and importance of PropTech is anything but, which is why many companies are trying to capitalize on the rapidly growing paradigm shift, while Universal PropTech (UPI:TSXV) is actually delivering healthy building solutions developers, owners and operators across Canada.
This is comprised of awarded and not executed work, made up of a combination of service contracts and project work in both HVAC Building Automation and Mechanical lines of business.
We sat down with Frank Carnevale, CGO of Universal Proptech, to talk about their multimillion-dollar backlog. Check out the full interview below.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, PA-C discuss whether or not the mystical experience caused by many psychedelic medicines is a necessary factor for the healing they promote.
Microdose covers ketamine’s history as an off-label treatment for depression, the FDA approval of Spravatoᵀᴹ (esketamine) and what the future looks like for these drugs. CEO Yaron Conforti and CMO Dr. Reid Robison were both interviewed for the article.
“Cost and accessibility are universal challenges we face in our healthcare system, and these will also apply to psilocybin, MDMA, and nearly every drug that comes to market, at least during the initial years of patent exclusivity,” said Robison.
We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a study titled “A phase IIb, randomized, double blind, two arm study to investigate the effects of BNC210 tablet formulation compared to placebo in adults with post-traumatic stress disorder”.
“This clinical trial leverages CCR’s established track record studying novel treatments for PTSD and other difficult to treat mental health conditions.” said Dr. Reid Robison, Chief Medical Officer of Novamind.
Larger and stronger neural connections. According to new research out of Yale, it’s all about the increased density of dendritic spines. “Small protrusions found on nerve cells which aid in the transmission of information between neurons. Chronic stress and depression are known to reduce the number of these neuronal connections.” If psilocybin can create larger and stronger neural connections, the potential for treating depression and creating lasting change improves significantly.
While “there have been no research studies in humans showing that LSD can treat allergies of any kind” one patent application hopes that one day LSD will be able to treat food allergies. The article references a story about a claim (not research- or evidence-based) that LSD cured a lifelong cat allergy and goes into more detail about the patent process and what might stand in the way of this one getting approved. “It’s based on luck.” And it’s another entrant to the race to patent psychedelics.
Posted by AGORACOM-JC
at 4:53 PM on Tuesday, July 6th, 2021
HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing a portfolio of high value-added silicon products sought after by battery and electric vehicle manufacturers.
If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following:
To understand the importance and the implications of this milestone, this excerpt from the press release says it all:
” Demand for higher purity Silicon, materials that the PUREVAP QRR was designed to produce – but one that traditional silicon producers have a difficult time making, is about to enter a massive growth phase, driven by worldwide demand from the silicones, solar, and batteries industries. The Covid-19 pandemic accelerated the closing of old inefficient traditional Silicon plants and combining this with the chronic under investment in new conventional Silicon plants that occurred in the past decade, and the need for more efficient and environmentally friendly processes has created a perfect storm for the industry. HPQ should be a key beneficiary of this new reality.”
Today, thanks to HPQ’s great progress on its silicon mission, the Company announced “An Agreement to Develop a New Environmentally Friendly Process to Manufacture Fumed Silica” What is Fumed Silica? Suffice it to say, it is in heavy demand right now but current producers are going to run into strong environmental “ESG” headwinds as the industry is now moving towards clean and verified Fumed Silica that HPQ Silicon believes it will be able to deliver thanks to its powerful relationship with ESG driven PyroGenesis Canada. The market for Fumed Silica is set to hit $USD 2.2 Billion in 2022 and CEO Tourillon wasn’t shy about his confidence in the Company’s potential to win market share with this quote:
““The business opportunity that this represent should not be underestimated and could be as significant as the ones represented by the PUREVAP™ family of processes we are developing with PyroGenesis”
Watch this great interview with $HPQ CEO Bernard Tourillon – especially the last 13 minutes – to get the full picture!
Posted by AGORACOM-JC
at 6:17 PM on Monday, July 5th, 2021
With $US 3.2M in 2020 revenue, representing a 58% increase over the previous year, you would think Empower Clinics CEO Steve McAuley would use his first interview after the filing to celebrate.
He isn’t.
Rather, with Fiscal 2020 having come to end more than 6 months ago, the 2020 results are a distant rear view mirror shot of a Company that is in full-blown growth mode and can be best summarized as follows:
“Multiple opportunities have been percolating and I’m going to turn up the heat”
To this end McAuley sees a “substantially higher market cap” for the Company, as well as, growth that will be “deserving of an uplist”.
We could try to list all the powerful things he had to say in this interview – but best we let you watch/hear it straight from Steve in this amazing interview.
Posted by AGORACOM-JC
at 12:23 PM on Monday, July 5th, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
The smile on CEO Steve Saviuk says it all. The company recently released Q2 results and highlights:
Q2-21 record revenues of $2.65 million, up 27% vs Q2-20 and up 42% over prior quarter
Q3-21 revenues expected to increase by more than 50% over Q2-21
Redesca (blood thinner) launched in late Q2-21
Commercial shipments of the company’s asthma drugs commenced following national respiratory sales force deployment
Closed upsized $6.645 million debenture placement
Closed $11.5 million bought deal
As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025.
Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison and Dr. Steve Thayer discuss how to integrate a psychedelic experience into everyday life.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison and Dr. Steve Thayer are joined by Derick Moody, PA-C, to discuss the role that the inner healing intelligence plays in psychedelic medicine.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison and Dr. Steve Thayer discuss the historically messy relationship between spirituality and modern psychiatry and the role that psychedelics are playing in a spiritual renaissance.
The Podcast is hosted by Novamind’s Dr. Stephen Thayer, Clinical Director, Education & Training and Dr. Reid Robison, Chief Medical Officer. Weekly Podcast episodes feature conversations between Dr. Thayer and Dr. Robison about issues that are of special interest to the psychedelic medicine and research community.
“Psychedelics are the next frontier of psychiatric medicine, and we’re helping professionals learn more about our specialized practice with actionable information. The need for specialized tools in mental healthcare has never been greater,” said Dr. Thayer.
Zoe Boyer writes about her lifelong struggle with depression: “Over the years I tried every available treatment. I stayed in psychiatric hospitals, underwent years of therapy and tried a pharmacy’s worth of antidepressants, but my condition never improved. One day, I stumbled across an article on the use of ketamine as a promising treatment for severe, unresponsive depression.” After four sessions, everything changed. “When my brother got his first pair of glasses, he marveled that he could see individual leaves on trees. Ketamine felt a lot like that. To be in awe of simple pleasures felt like reason enough to live, and I was overcome with a quiet revelation: this is what it means to be content.” Zoe’s story is similar to many who have had life changing experiences with Ketamine. We see it every day at our Cedar Psychiatry clinics. This video shares the stories of just a few of the thousands of patients we’ve treated.
How one state senator’s bill to decriminalize psilocybin, MDMA, LSD, DMT, mescaline and ibogaine is gaining steam in California. Former army rangers and marine corps veterans are quoted about how psychedelics offered them something they found nowhere else: hope and lasting change. “I will say this unequivocally psychedelics have, and will, save veteran lives.”
Green Market Report covers our strategic investment of $1 million in a Stealth Mode Drug Development Company. Psychedellux recaps the top business stories in the psychedelic medicine industry.
Last week we announced a strategic investment of $1 million in a stealth mode drug development company based in the United States.
Report on Psychedelics covers our Frontline KAP program, which addresses a glaring need for innovative mental health solutions to provide treatment to healthcare workers suffering stress and trauma caused by Covid-19.
COVID-19 put a toll on the mental health of frontline healthcare workers. Novamind and the Wholeness Center will launch a ketamine-assisted psychotherapy protocol, in Utah and Colorado.
Dr. Thielking will oversee all aspects of the Company’s investigator-led studies, originating within Novamind’s best-in-class research sites, and leveraging its contract research organization (CRO) expertise to pursue additional clinical trial mandates from leading psychedelic drug developers.
“Advancing clinical research for psychedelic medicine to address treatment-resistant mental illnesses and supporting patients by developing novel approaches to care for underserved conditions like cancer-related depression, is the next step in my life’s work,” said Dr. Thielking.
It’s a lawsuit that may be more of an “educational vehicle” for the Justice Department and the DEA than a legal battle. Under Washington state’s Right to Try law, Erinn Baldeschwiler should have the right to use psilocybin therapeutically, but the DEA has denied her request. Baldeschwiler may only have two years left and doesn’t want those years to be marred by depression. This case could set a precedent for the future “if the case passes, the next doctor and patient who want access to psilocybin for end-of-life distress shouldn’t need to take it to court again.” We understand the positive impact psychedelic medicine can have and will watch this case closely as we prepare to bring more psychedelic-assisted psychotherapies to the world. This week, Novamind announced Dr. Paul Thielking as Chef Scientific Officer. Dr. Thielking will lead the development of Novamind’s psychedelic therapy protocols for conditions including cancer-related depression and end-of-life anxiety, available as treatments for clients and educational programs for clinicians.
Could changing the approach to the medical model transform the way we treat people? It’s a concept Natasha Fearnley believes in. “I’m beginning to guide them [people] through their journey. And I can’t imagine doing that without ever having any psychedelic experience.” TheraPsil agrees. “The non-profit believes that in order for healthcare professionals to deliver this “unique therapeutic modality” it’s essential that they undergo their own psilocybin journeys and guide their peers through the psilocybin therapy process.”
Posted by AGORACOM-JC
at 2:23 PM on Wednesday, June 23rd, 2021
HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing a portfolio of high value-added silicon products sought after by battery and electric vehicle manufacturers.
If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following
To understand the importance and the implications of this milestone, this excerpt from the press release says it all:
” Demand for higher purity Silicon, materials that the PUREVAP QRR was designed to produce – but one that traditional silicon producers have a difficult time making, is about to enter a massive growth phase, driven by worldwide demand from the silicones, solar, and batteries industries. The Covid-19 pandemic accelerated the closing of old inefficient traditional Silicon plants and combining this with the chronic under investment in new conventional Silicon plants that occurred in the past decade, and the need for more efficient and environmentally friendly processes has created a perfect storm for the industry. HPQ should be a key beneficiary of this new reality.”
